Abstract
Background: Atherosclerosis (AS) is a major cause of death and morbidity in Western world and is strongly connected with atherogenic lipoproteins and inflammation. Bile acids (BA) act as activating signals of endogenous ligands such as Farnesoid-X receptor (FXR). Primary data indicate a potential role of FXR in AS. The therapeutic value of FXR ligands in AS is unknown.
Objective: With the present review, we analyzed the efficacy of FXR agonists as a therapeutic modalities against AS. In this aspect, we performed an electronic search through Pub- Med/MEDLINE database by using the key terms: FXR*, Farnesoid X receptor*, atherosclerosis*, bile acids* and agonism*. Conclusion: According to our analysis, the FXR seems to be a promising therapeutic target in the atherosclerosis natural history. FXR agonism could exert protective effects in the development and evolution of AS. However, concomitant side effects such as the reduction of plasma HDL have been reported. Finally, results from undergoing clinical trials with synthetic FXR agonists will shed more light to the precise role of FXR agonism in AS treatment.Keywords: FXR, atherosclerosis, agonist, bile acids, pharmaceutical target, clinical trials.
Current Medicinal Chemistry
Title:Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
Volume: 24 Issue: 11
Author(s): Demetrios Moris, Constantinos Giaginis*, Gerasimos Tsourouflis and Stamatios Theocharis
Affiliation:
- Department of Food Science and Nutrition, University of the Aegean, 2 Mitropoliti Ioakeim Street, Myrina, Lemnos 81400,Greece
Keywords: FXR, atherosclerosis, agonist, bile acids, pharmaceutical target, clinical trials.
Abstract: Background: Atherosclerosis (AS) is a major cause of death and morbidity in Western world and is strongly connected with atherogenic lipoproteins and inflammation. Bile acids (BA) act as activating signals of endogenous ligands such as Farnesoid-X receptor (FXR). Primary data indicate a potential role of FXR in AS. The therapeutic value of FXR ligands in AS is unknown.
Objective: With the present review, we analyzed the efficacy of FXR agonists as a therapeutic modalities against AS. In this aspect, we performed an electronic search through Pub- Med/MEDLINE database by using the key terms: FXR*, Farnesoid X receptor*, atherosclerosis*, bile acids* and agonism*. Conclusion: According to our analysis, the FXR seems to be a promising therapeutic target in the atherosclerosis natural history. FXR agonism could exert protective effects in the development and evolution of AS. However, concomitant side effects such as the reduction of plasma HDL have been reported. Finally, results from undergoing clinical trials with synthetic FXR agonists will shed more light to the precise role of FXR agonism in AS treatment.Export Options
About this article
Cite this article as:
Moris Demetrios, Giaginis Constantinos*, Tsourouflis Gerasimos and Theocharis Stamatios, Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis, Current Medicinal Chemistry 2017; 24 (11) . https://dx.doi.org/10.2174/0929867324666170124151940
DOI https://dx.doi.org/10.2174/0929867324666170124151940 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure
Cardiovascular & Hematological Disorders-Drug Targets The Medicinal Chemistry of Peptides
Current Medicinal Chemistry The Role of Vitamin D in Atherosclerosis Inflammation Revisited: More a Bystander than a Player?
Current Vascular Pharmacology Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure
Current Vascular Pharmacology Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
Current Diabetes Reviews Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
Current Medicinal Chemistry TGFb and its Smad Connection to Cancer
Current Genomics New Insights on the Mode of Action of Microcystins in Animal Cells - A Review
Mini-Reviews in Medicinal Chemistry Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity
Current Drug Targets A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure
Current Pharmaceutical Design Modulating Poly (ADP-Ribose) Polymerase Activity: Potential for the Prevention and Therapy of Pathogenic Situations Involving DNA Damage and Oxidative Stress
Current Pharmaceutical Biotechnology The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Propofol Promotes Blood-Brain Barrier Breakdown and Heat Shock Protein (HSP 72 kd) Activation in the Developing Mouse Brain
CNS & Neurological Disorders - Drug Targets Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics
Current Drug Metabolism Efficacy and Cardiovascular Safety of Sulfonylureas
Current Drug Safety Phenotypes and Enviromental Factors: Their Influence in PCOS
Current Pharmaceutical Design Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets Treating and Preventing No Reflow in the Cardiac Catheterization Laboratory
Current Cardiology Reviews